Insider · CIK 0001588862
Charles McWherter
Files at CBAY (CymaBay Therapeutics, Inc.), ETNB (89bio, Inc.). First filing Oct 18, 2023, latest Jan 23, 2025.
In brief
Charles McWherter files SEC Form 4 as director and president at CBAY (CymaBay Therapeutics, Inc.), and also at ETNB (89bio, Inc.). Since Oct 18, 2023, Charles McWherter has reported 2 open-market buys worth $180k and 3 open-market sells worth $757k, the latest filed on Jan 23, 2025.
A track record needs three past buys with six months of prices behind them; Charles McWherter has 0, so none is measured yet.
The newest scored trade: bought $100k of ETNB on Jan 21, 2025, filed Jan 23, 2025, scored 48 (moderate).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 48Moderate | 89bio, Inc. | $100k 15,000 shares | +150% | - | |
| 40Moderate | 89bio, Inc. | $80k 10,000 shares | - | - | |
| 33Weak | CymaBay Therapeutics, Inc. | $243k 11,332 shares | -57% | - | |
| 22Weak | CymaBay Therapeutics, Inc. | $207k 11,342 shares | -43% | - | |
| 27Weak | CymaBay Therapeutics, Inc. | $306k 21,743 shares | -59% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 18, 2023 | CYMABAY THERAPEUTICS, INC. | 11,332 0.01% of outstanding | $243k | Dec 18, 2023 | $513k |
| Nov 17, 2023 | CYMABAY THERAPEUTICS, INC. | 11,342 0.01% of outstanding | $207k | Nov 17, 2023 | $908k |
| Oct 18, 2023 | CYMABAY THERAPEUTICS, INC. | 21,743 0.02% of outstanding | $306k | Oct 18, 2023 | $602k |
Transactions
Every row this insider has filed, 28 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 30, 2025 | ETNB 89bio, Inc. | UTender of shares Common Stock | -25,000 | - | - | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -67,700 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | ETNB 89bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -56,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Feb 3, 2025 | ETNB 89bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +56,400 | $0.00 | $0 | 56,400 | Feb 5, 2025 |
| Jan 21, 2025 | ETNB 89bio, Inc. | POpen-market purchase Common Stock | +5,000 | $6.55 | $33k | 15,000 | Jan 23, 2025 |
| Jan 22, 2025 | ETNB 89bio, Inc. | POpen-market purchase Common Stock | +10,000 | $6.71 | $67k | 25,000 | Jan 23, 2025 |
| Dec 5, 2024 | ETNB 89bio, Inc. | POpen-market purchase Common Stock | +10,000 | $8.00 | $80k | 10,000 | Dec 9, 2024 |
| Dec 18, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Common Stock | +4,828 | $5.00 | $24k | 19,828 | Dec 18, 2023 |
| Dec 18, 2023 | CBAY CymaBay Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -4,828 | $21.49 | $104k | 15,000 | Dec 18, 2023 |
| Dec 18, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Common Stock | +6,504 | $5.00 | $33k | 21,504 | Dec 18, 2023 |
| Dec 18, 2023 | CBAY CymaBay Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -6,504 | $21.48 | $140k | 15,000 | Dec 18, 2023 |
| Dec 18, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -704 | $0.00 | $0 | 0 | Dec 18, 2023 |
| Dec 18, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -234 | $0.00 | $0 | 0 | Dec 18, 2023 |
| Dec 18, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -3,890 | $0.00 | $0 | 0 | Dec 18, 2023 |
| Dec 18, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -6,504 | $0.00 | $0 | 0 | Dec 18, 2023 |
| Nov 17, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Common Stock | +11,342 | $5.00 | $57k | 26,342 | Nov 17, 2023 |
| Nov 17, 2023 | CBAY CymaBay Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -11,342 | $18.28 | $207k | 15,000 | Nov 17, 2023 |
| Nov 17, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -708 | $0.00 | $0 | 704 | Nov 17, 2023 |
| Nov 17, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -236 | $0.00 | $0 | 234 | Nov 17, 2023 |
| Nov 17, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -3,892 | $0.00 | $0 | 3,890 | Nov 17, 2023 |
| Nov 17, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -6,506 | $0.00 | $0 | 6,504 | Nov 17, 2023 |
| Oct 18, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Common Stock | +21,743 | $5.00 | $109k | 36,743 | Oct 18, 2023 |
| Oct 18, 2023 | CBAY CymaBay Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -21,743 | $14.07 | $306k | 15,000 | Oct 18, 2023 |
| Oct 18, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -10,401 | $0.00 | $0 | 0 | Oct 18, 2023 |
| Oct 18, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -708 | $0.00 | $0 | 1,412 | Oct 18, 2023 |
| Oct 18, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -236 | $0.00 | $0 | 470 | Oct 18, 2023 |
| Oct 18, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -3,892 | $0.00 | $0 | 7,782 | Oct 18, 2023 |
| Oct 18, 2023 | CBAY CymaBay Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -6,506 | $0.00 | $0 | 13,010 | Oct 18, 2023 |
Questions about Charles McWherter
Answered from the filings on this page, as of the latest one.
Is Charles McWherter buying or selling?
Not in the last 12 months. Charles McWherter's latest open-market trade on SEC Form 4 was bought $100k of ETNB on Jan 21, 2025.
How did Charles McWherter's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Charles McWherter has 0.
Where does Charles McWherter file Form 4?
Charles McWherter has filed Form 4 at CBAY (CymaBay Therapeutics, Inc.) as President of R&D; ETNB (89bio, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.